Press Releases

Read our latest announcements

Filter by year:

2017-04-24
Modus Therapeutics appoints Ellen K. Donnelly, Ph.D. as CEO

STOCKHOLM, SWEDEN – 24 April, 2017. Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle cell disease (SCD), announces the appointment of Ellen K. Donnelly, Ph.D as Chief Executive Officer. Modus Therapeutics’ lead drug candidate sevuparin is currently in a Phase II clinical trial in patients with […]

View Press Release
2017-02-20
Modus Therapeutics raises SEK 32 million to support further development of sevuparin for sickle cell disease

STOCKHOLM, SWEDEN – 20 February, 2017. Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle cell disease, announces the successful completion of a financing round raising SEK 32 million from existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest.  Modus Therapeutics is currently recruiting patients in Europe, the Middle East and […]

View Press Release